Announcing a new partnership, Autolomous and Vineti say they are integrating their technology to ensure scalability when cell and gene therapies become standard of care.
NICE recommends CAR T-cell treatment Kymirah to be covered by the Cancer Drugs Fund to treat adult patients with lymphoma, despite previous negative appraisals.
